In a cancer vaccine setback, the drug giant GlaxoSmithKline (GSK) announced yesterday that an immunotherapy it had been testing in a phase III trial had flopped. The company is holding out hope, however, that some patients with a certain genetic …
MRV Research
8th World Congress of Melanoma Research 2013
The first Melanoma Congress was held in Venice in 1985 and has been held every four years since. The most recent Congress, held in Hamburg Germany from the 17-20th July…
Read More Marker Could Predict Dabrafenib Response in Melanoma
An article in CancerNetwork discusses how results show that the BRAF inhibitor dabrafenib was effective in the treatment of patients with advanced melanoma. Please read further on how a marker could predict dabrafenib response in Melanoma.
Cancer treatment used by GP chief Ron Walker raises hope
Herald Sun reported how the drug lambrolizumab is producing promising results. Read how the drug is saving Dr Ron Walker’s life and is fuelling hopes around the world as a promising new approach to overcoming cancer.